Rapt Therapeutics Stock News

Cantor assumes coverage of RAPT Therapeutics Inc (NASDAQ: RAPT) with an Overweight rating and a price target of $44 (vs. $58 previously).  The analyst says the company's RPT193 (lead inflammation

Analysts have provided the following ratings for RAPT Therapeutics (NASDAQ:RAPT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0

Although the Dow Jones jumped by more than 400 points on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or tha

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -4.55% and 60.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -4.55% and 60.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 12.50% and 31.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the

RAPT Therapeutics (NASDAQ: RAPT ) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings RAPT Therapeutics beat estimated earnings by 7.58%, reporting an EPS of … Full story available on Benzinga.com

RAPT Therapeutics press release (RAPT): Q4 GAAP EPS of -$0.61 beats by $0.06.Revenue of $0.75M (-42.3% Y/Y) beats by $0.26M.

Company maintains strong cash position of $189.7 million Company maintains strong cash position of $189.7 million

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.67% and 71.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

RAPT Therapeutics Inc. (NASDAQ:RAPT) concluded the trading at $19.08 on Friday, February 25 with a fall of -0.47% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $19.17 and 5Y monthly beta was reading 0.13 with its price kept floating in the … RAPT Therapeutics Inc. (RAPT) Is Worth A Look Now, Despite -55.89% Loss From High Read More »

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock

RAPT Therapeutics Inc (RAPT) shares closed this week 24.3% lower than it did at the end of last week. The stock is currently down 19.4% year-to-date, up 41.6% over the past 12 months, and up 127.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $38.34 and as low as $27.57 this week.Shares closed 31.6% below its 52-week high and 98.8% above its 52-week low.Trading volume this week was 4.8% lower than the 10-day average and 0.4% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3130.1% The company's stock price performance over the past 12 months beats the peer average by -372.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

RAPT Therapeutics <> has recorded its biggest intraday loss since November 2020 on below-average volume as the clinical-stage biotech prepares for a presentation at a major…